⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 21, 2024Frontiers in OncologyOpen Access

Efficacy and safety analysis of combination therapy based on mitoxantrone hydrochloride liposome injection (Lipo-MIT) in relapsed/refractory NK/T-cell lymphoma

Xing-long Wang He-nan Wang Lei Yang Jing Yang Jia Cong Song Zhi-hui Liang Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Currently, there is no standard treatment for relapsed/refractory NK/T-cell lymphoma (NKTCL). Liposomal mitoxantrone (Lipo-MIT) showed good anti-tumor effect in patients with NKTCL, breaking the limitation of natural resistance of NKTCL to anthracyclines. To further improve the efficacy, we tried a combination therapy based on Lipo-MIT in patients with relapsed/refractory NKTCL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e63c18b6db6435875ce277 https://doi.org/10.3389/fonc.2024.1396819

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trialHuman Clinical Trial · 2026
2The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemiareview · 2023 · 1 citations
3Combination of mitoxantrone hydrochloride liposome with chidamide in patients with relapsed or refractory peripheral T cell lymphoma: Updated results of the phase II study2025 · 1 citations
4Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I studyEarly-Phase Clinical Trial · 2026
5Mitoxantrone liposome combined with EAC autologous transplant conditioning for the treatment of T/NK non-Hodgkin's lymphoma2025

More related papers

Pharmacokinetics, Efficacy, and Safety Profiles of Mitoxantrone Hydrochloride Liposome Plus Cytarabine in Pediatric Patients With Newly Diagnosed Acute Myeloid Leukemia2026
An open-label, single-center phase II trial of mitoxantrone hydrochloride liposome combined with programmed death-1 (PD-1) inhibitors for pretreated recurrent or metastatic nasopharyngeal carcinoma.2026
Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with azacitidine and Chidamide can be an effective chemotherapy regimen for patients with angioimmunoblastic T-cell lymphoma (AITL)2025

More from Frontiers in Oncology

Management of cardiometabolic risk in prostate cancer: expert consensus from Singapore and MalaysiaWed,
Sarcomatoid urothelial carcinoma of the urethra with an unusual right ventricular metastasis: a case report and review of literatureWed,